Symbols / BBNX Stock $14.39 +3.75% Beta Bionics, Inc.

Healthcare • Medical Devices • United States • NGM
BBNX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. Sean T. Saint PE
Exch · Country NGM · United States
Market Cap 641.24M
Enterprise Value 448.63M
Income -66.44M
Sales 110.24M
FCF (ttm) -44.06M
Book/sh 6.09
Cash/sh 4.48
Employees 420
Insider 10d —
IPO Jan 30, 2025
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -6.02
PEG —
P/S 5.82
P/B 2.36
P/C —
EV/EBITDA -5.95
EV/Sales 4.07
Quick Ratio 9.38
Current Ratio 10.69
Debt/Eq 2.55
LT Debt/Eq —
EPS (ttm) -1.37
EPS next Y -2.39
EPS Growth —
Revenue Growth 56.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-07-21
Earnings (prior) 2026-04-21
ROA -15.04%
ROE -22.71%
ROIC —
Gross Margin 57.15%
Oper. Margin -87.86%
Profit Margin -60.27%
Shs Outstand 44.56M
Shs Float 25.34M
Insider Own 1.10%
Instit Own 112.60%
Short Float 11.73%
Short Ratio 7.52
Short Interest 5.20M
52W High 32.71
vs 52W High -56.01%
52W Low 8.80
vs 52W Low 63.52%
Beta —
Impl. Vol. 28.13%
Rel Volume 0.91
Avg Volume 972.47K
Volume 880.78K
Target (mean) $19.18
Tgt Median $18.00
Tgt Low $13.00
Tgt High $32.00
# Analysts 11
Recom Buy
Prev Close $13.87
Price $14.39
Change 3.75%
About

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$19.18
Mean price target
2. Current target
$14.39
Latest analyst target
3. DCF / Fair value
$-17.80
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$14.39
Low
$13.00
High
$32.00
Mean
$19.18

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-27 main Goldman Sachs Buy → Buy $17
2026-05-18 main B of A Securities Neutral → Neutral $11
2026-04-22 main Leerink Partners Outperform → Outperform $24
2026-04-22 main Stifel Buy → Buy $20
2026-04-15 main Truist Securities Buy → Buy $18
2026-04-09 main Goldman Sachs Buy → Buy $20
2026-02-18 main Stifel Buy → Buy $22
2026-02-18 main Baird Neutral → Neutral $14
2026-02-04 main Stifel Buy → Buy $25
2026-02-02 main Truist Securities Buy → Buy $25
2026-01-27 init TD Cowen — → Hold $17
2026-01-09 main Lake Street Buy → Buy $40
2026-01-05 main B of A Securities Buy → Buy $33
2025-12-18 main Truist Securities Buy → Buy $37
2025-10-29 main Goldman Sachs Buy → Buy $33
2025-10-29 reit Stifel Buy → Buy $31
2025-10-29 reit Truist Securities Buy → Buy $32
2025-10-29 reit Piper Sandler Overweight → Overweight $32
2025-10-01 up Goldman Sachs Neutral → Buy $26
2025-09-22 main Truist Securities Buy → Buy $28
News
RSS: Latest BBNX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-04 HOPMAN MARK Officer — 275 $12.31 $3,385
2026-06-04 JONES CHRISTY Director — 2,811 $14.00 $39,354
2026-06-02 SAINT SEAN Chief Executive Officer — 16,872 $12.61 $212,707
2026-06-02 FEIDER STEPHEN Chief Financial Officer — 6,676 $12.61 $84,165
2026-06-02 HOPMAN MARK Officer — 5,329 $12.61 $67,183
2026-06-02 MENSINGER MIKE Officer — 4,378 $12.61 $55,194
2026-06-02 RUSSELL STEVEN JON Officer — 4,222 $12.61 $53,227
2026-05-22 LEZACK ADAM Director — 1,998 $9.95 $21,138
2026-05-21 MICHEL GERARD J Director — 16,965 $0.00 $0
2026-05-21 CARNEY SEAN D Director — 16,965 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
100.25
+53.94%
65.12
+442.93%
11.99
+6601.12%
0.18
Operating Revenue
100.25
+53.94%
65.12
+442.93%
11.99
+6601.12%
0.18
Cost Of Revenue
44.71
+52.94%
29.24
+414.08%
5.69
—
Reconciled Cost Of Revenue
44.71
+52.94%
29.24
+414.08%
5.69
—
Gross Profit
55.54
+54.75%
35.89
+468.93%
6.31
+3424.02%
0.18
Operating Expense
127.22
+56.79%
81.14
+92.46%
42.16
-36.15%
66.02
Research And Development
34.79
+32.86%
26.18
+45.93%
17.94
-42.91%
31.43
Selling General And Administration
92.43
+68.19%
54.95
+126.95%
24.21
-30.00%
34.59
Selling And Marketing Expense
61.40
+65.57%
37.09
+209.31%
11.99
+42.01%
8.44
General And Administrative Expense
31.02
+73.62%
17.87
+46.17%
12.22
-53.25%
26.15
Salaries And Wages
—
—
3.64
-19.97%
4.55
Other Gand A
31.02
+73.62%
17.87
+46.17%
12.22
-43.42%
21.61
Total Expenses
171.93
+55.77%
110.38
+130.69%
47.84
-27.53%
66.02
Operating Income
-71.68
-58.41%
-45.25
-26.22%
-35.85
+45.55%
-65.84
Total Operating Income As Reported
-71.68
-58.41%
-45.25
-26.22%
-35.85
+45.55%
-65.84
EBITDA
-68.81
-60.13%
-42.97
-27.28%
-33.76
+46.11%
-62.65
Normalized EBITDA
-56.36
-90.68%
-29.56
-24.18%
-23.80
+62.55%
-63.56
Reconciled Depreciation
2.88
+25.93%
2.28
+9.18%
2.09
+0.19%
2.09
EBIT
-71.68
-58.41%
-45.25
-26.22%
-35.85
+44.62%
-64.74
Total Unusual Items
-12.45
+7.17%
-13.41
-34.69%
-9.96
-1193.08%
0.91
Total Unusual Items Excluding Goodwill
-12.45
+7.17%
-13.41
-34.69%
-9.96
-1193.08%
0.91
Net Income
-73.20
-33.68%
-54.76
-24.17%
-44.10
+31.89%
-64.75
Pretax Income
-73.20
-33.68%
-54.76
-24.17%
-44.10
+31.89%
-64.75
Net Non Operating Interest Income Expense
10.93
+179.66%
3.91
+119.98%
1.78
+876.37%
0.18
Interest Expense Non Operating
—
—
0.07
+385.71%
0.01
Net Interest Income
10.93
+179.66%
3.91
+119.98%
1.78
+876.37%
0.18
Interest Expense
—
—
0.07
+385.71%
0.01
Interest Income Non Operating
10.93
+179.66%
3.91
+119.98%
1.78
+806.63%
0.20
Interest Income
10.93
+179.66%
3.91
+119.98%
1.78
+806.63%
0.20
Other Income Expense
-12.45
+7.18%
-13.41
-33.79%
-10.03
-1200.55%
0.91
Other Non Operating Income Expenses
-0.00
+50.00%
-0.00
+97.06%
-0.07
—
Gain On Sale Of Security
-12.45
+7.17%
-13.41
-34.69%
-9.96
-1193.08%
0.91
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-73.20
-33.68%
-54.76
-24.17%
-44.10
+31.89%
-64.75
Net Income From Continuing Operation Net Minority Interest
-73.20
-33.68%
-54.76
-24.17%
-44.10
+31.89%
-64.75
Net Income From Continuing And Discontinued Operation
-73.20
-33.68%
-54.76
-24.17%
-44.10
+31.89%
-64.75
Net Income Continuous Operations
-73.20
-33.68%
-54.76
-24.17%
-44.10
+31.89%
-64.75
Normalized Income
-60.75
-46.94%
-41.34
-21.10%
-34.14
+48.00%
-65.66
Net Income Common Stockholders
-73.20
-33.68%
-54.76
-24.17%
-44.10
+31.89%
-64.75
Diluted EPS
-1.81
-41.67%
-1.28
+11.65%
-1.45
+31.89%
-2.12
Basic EPS
-1.81
-41.67%
-1.28
+11.65%
-1.45
+31.89%
-2.12
Basic Average Shares
40.53
-5.44%
42.86
+40.54%
30.50
+0.00%
30.50
Diluted Average Shares
40.53
-5.44%
42.86
+40.54%
30.50
+0.00%
30.50
Diluted NI Availto Com Stockholders
-73.20
-33.68%
-54.76
-24.17%
-44.10
+31.89%
-64.75
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
328.74
+119.68%
149.65
+35.99%
110.04
+209.74%
35.53
Current Assets
267.90
+101.55%
132.92
+28.28%
103.62
+264.00%
28.47
Cash Cash Equivalents And Short Term Investments
219.12
+111.56%
103.58
+7.06%
96.75
+249.58%
27.68
Cash And Cash Equivalents
31.58
+3.76%
30.43
+14.55%
26.57
-4.01%
27.68
Other Short Term Investments
187.55
+156.41%
73.14
+4.22%
70.18
0.00
Receivables
19.89
+52.49%
13.05
+193.30%
4.45
0.00
Accounts Receivable
17.12
+42.70%
12.00
+169.69%
4.45
0.00
Gross Accounts Receivable
17.27
+42.62%
12.11
+169.51%
4.49
—
Allowance For Doubtful Accounts Receivable
-0.16
-34.48%
-0.12
-152.17%
-0.05
—
Taxes Receivable
0.27
-67.56%
0.82
—
—
Accrued Interest Receivable
2.51
+977.68%
0.23
—
—
Inventory
21.72
+63.08%
13.32
+969.88%
1.25
0.00
Raw Materials
8.56
+27.00%
6.74
+738.98%
0.80
—
Work In Process
2.75
+331.71%
0.64
+1773.53%
0.03
—
Finished Goods
10.42
+75.18%
5.95
+1357.35%
0.41
—
Prepaid Assets
7.06
+136.89%
2.98
+228.41%
0.91
+67.53%
0.54
Restricted Cash
0.10
0.00
—
—
Other Current Assets
—
1.05
+281.82%
0.28
+10.00%
0.25
Total Non Current Assets
60.84
+263.82%
16.72
+160.51%
6.42
-9.08%
7.06
Net PPE
15.23
+33.32%
11.42
+84.27%
6.20
-9.74%
6.87
Gross PPE
20.98
+25.84%
16.67
+57.04%
10.62
+3.68%
10.24
Accumulated Depreciation
-5.75
-9.56%
-5.25
-18.85%
-4.42
-31.00%
-3.37
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.94
-23.78%
1.23
-11.49%
1.39
-10.31%
1.55
Construction In Progress
3.34
+92.45%
1.74
+938.92%
0.17
-8.24%
0.18
Other Properties
15.87
+23.08%
12.90
+59.07%
8.11
+7.31%
7.56
Leases
0.83
+2.47%
0.81
-14.83%
0.95
+0.00%
0.95
Investments And Advances
45.43
0.00
—
—
Non Current Deferred Assets
0.00
-100.00%
5.05
0.00
—
Other Non Current Assets
0.18
-28.00%
0.25
+13.12%
0.22
+14.51%
0.19
Total Liabilities Net Minority Interest
41.13
-89.59%
395.00
+26.14%
313.14
+52.34%
205.56
Current Liabilities
30.92
+46.23%
21.15
+99.42%
10.61
+19.52%
8.87
Payables And Accrued Expenses
12.84
+65.78%
7.74
+130.68%
3.36
+43.95%
2.33
Payables
5.00
+75.25%
2.85
+144.60%
1.17
-25.73%
1.57
Accounts Payable
5.00
+75.25%
2.85
+144.60%
1.17
+171.16%
0.43
Current Accrued Expenses
7.84
+60.26%
4.89
+123.28%
2.19
+187.53%
0.76
Pensionand Other Post Retirement Benefit Plans Current
12.66
+27.30%
9.94
+81.59%
5.47
+1.75%
5.38
Current Debt And Capital Lease Obligation
1.94
+26.75%
1.53
+24.92%
1.22
+25.41%
0.98
Current Capital Lease Obligation
1.94
+26.75%
1.53
+24.92%
1.22
+25.41%
0.98
Current Deferred Liabilities
1.56
+65.81%
0.94
+979.31%
0.09
0.00
Current Deferred Revenue
1.56
+65.81%
0.94
+979.31%
0.09
0.00
Other Current Liabilities
0.33
-2.67%
0.34
-27.06%
0.46
+151.09%
0.18
Total Non Current Liabilities Net Minority Interest
10.21
-97.27%
373.86
+23.57%
302.54
+53.82%
196.69
Long Term Debt And Capital Lease Obligation
5.37
-6.30%
5.73
+90.93%
3.00
-5.00%
3.16
Long Term Capital Lease Obligation
5.37
-6.30%
5.73
+90.93%
3.00
-5.00%
3.16
Non Current Deferred Liabilities
3.30
+77.26%
1.86
+629.41%
0.26
0.00
Non Current Deferred Revenue
3.30
+77.26%
1.86
+629.41%
0.26
0.00
Other Non Current Liabilities
1.55
—
—
—
Preferred Securities Outside Stock Equity
0.00
-100.00%
321.37
+22.80%
261.71
+42.99%
183.03
Stockholders Equity
287.61
+217.22%
-245.36
-20.80%
-203.10
-19.45%
-170.03
Common Stock Equity
287.61
+217.22%
-245.36
-20.80%
-203.10
-19.45%
-170.03
Capital Stock
0.00
+300.00%
0.00
+0.00%
0.00
+0.00%
0.00
Common Stock
0.00
+300.00%
0.00
+0.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
—
—
Share Issued
44.36
+3.50%
42.86
+0.00%
42.86
+0.00%
42.86
Ordinary Shares Number
44.36
+3.50%
42.86
+0.00%
42.86
+0.00%
42.86
Additional Paid In Capital
657.14
+1180.70%
51.31
+94.21%
26.42
+70.13%
15.53
Retained Earnings
-369.94
-24.67%
-296.74
-29.20%
-229.66
-23.76%
-185.56
Gains Losses Not Affecting Retained Earnings
0.40
+520.00%
0.07
-52.55%
0.14
0.00
Other Equity Adjustments
0.40
+520.00%
0.07
-52.55%
0.14
—
Total Equity Gross Minority Interest
287.61
+217.22%
-245.36
-20.80%
-203.10
-19.45%
-170.03
Total Capitalization
287.61
+217.22%
-245.36
-20.80%
-203.10
-19.45%
-170.03
Working Capital
236.98
+112.02%
111.78
+20.17%
93.02
+374.72%
19.59
Invested Capital
287.61
+217.22%
-245.36
-20.80%
-203.10
-19.45%
-170.03
Total Debt
7.30
+0.66%
7.25
+71.80%
4.22
+2.18%
4.13
Capital Lease Obligations
7.30
+0.66%
7.25
+71.80%
4.22
+2.18%
4.13
Net Tangible Assets
287.61
+217.22%
-245.36
-20.80%
-203.10
-19.45%
-170.03
Tangible Book Value
287.61
+217.22%
-245.36
-20.80%
-203.10
-19.45%
-170.03
Available For Sale Securities
45.43
—
—
—
Current Provisions
1.61
+144.60%
0.66
—
—
Derivative Product Liabilities
0.00
-100.00%
44.90
+19.50%
37.57
+257.94%
10.50
Dueto Related Parties Current
—
—
0.00
-100.00%
1.14
Investmentin Financial Assets
45.43
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-50.92
-5.49%
-48.27
-48.78%
-32.45
+46.11%
-60.21
Cash Flow From Continuing Operating Activities
-50.92
-5.49%
-48.27
-48.78%
-32.45
+46.11%
-60.21
Net Income From Continuing Operations
-73.20
-33.68%
-54.76
-24.17%
-44.10
+31.89%
-64.75
Depreciation Amortization Depletion
2.88
+25.93%
2.28
+9.18%
2.09
+0.19%
2.09
Depreciation
2.88
+25.93%
2.28
+9.18%
2.09
+0.19%
2.09
Depreciation And Amortization
2.88
+25.93%
2.28
+9.18%
2.09
+0.19%
2.09
Other Non Cash Items
-1.99
—
—
0.01
Stock Based Compensation
16.38
+156.64%
6.38
+12.83%
5.66
-7.25%
6.10
Provisionand Write Offof Assets
1.52
+368.20%
-0.57
-4616.67%
-0.01
0.00
Operating Gains Losses
12.48
-7.10%
13.44
+34.77%
9.97
+1248.50%
-0.87
Gain Loss On Investment Securities
12.45
-7.17%
13.41
+34.69%
9.96
+1193.08%
-0.91
Gain Loss On Sale Of PPE
0.03
+34.78%
0.02
+109.09%
0.01
-74.42%
0.04
Change In Working Capital
-8.99
+25.98%
-12.15
-128.99%
-5.30
-90.14%
-2.79
Change In Receivables
-5.16
+32.24%
-7.62
-69.51%
-4.49
0.00
Changes In Account Receivables
-5.16
+32.24%
-7.62
-69.51%
-4.49
0.00
Change In Inventory
-9.88
+13.63%
-11.44
-863.69%
-1.19
0.00
Change In Prepaid Assets
-5.81
-103.86%
-2.85
-628.64%
-0.39
-428.57%
0.12
Change In Payables And Accrued Expense
9.52
+13.99%
8.35
+228.73%
2.54
+221.93%
-2.08
Change In Accrued Expense
7.42
+8.57%
6.84
+274.68%
1.82
+190.93%
-2.01
Change In Payable
2.10
+38.48%
1.51
+111.59%
0.72
+1029.87%
-0.08
Change In Account Payable
2.10
+38.48%
1.51
+111.59%
0.72
+1029.87%
-0.08
Change In Other Working Capital
2.06
-16.36%
2.46
+618.42%
0.34
+291.06%
-0.18
Change In Other Current Assets
-0.03
-3.45%
-0.03
-3.57%
-0.03
-132.56%
0.09
Change In Other Current Liabilities
0.31
+130.40%
-1.02
+51.01%
-2.09
-185.25%
-0.73
Investing Cash Flow
-162.81
-4583.69%
-3.48
+95.01%
-69.69
-8962.81%
-0.77
Cash Flow From Continuing Investing Activities
-162.81
-4583.69%
-3.48
+95.01%
-69.69
-8962.81%
-0.77
Net PPE Purchase And Sale
-5.30
-58.36%
-3.35
-740.45%
-0.40
+48.24%
-0.77
Purchase Of PPE
-5.30
-56.02%
-3.40
-744.53%
-0.40
+47.93%
-0.77
Sale Of PPE
0.00
-100.00%
0.05
+1150.00%
0.00
+33.33%
0.00
Capital Expenditure
-5.30
-56.02%
-3.40
-744.53%
-0.40
+47.93%
-0.77
Net Investment Purchase And Sale
-157.51
-120135.11%
-0.13
+99.81%
-69.30
0.00
Purchase Of Investment
-327.51
-354.05%
-72.13
-4.09%
-69.30
0.00
Sale Of Investment
170.00
+136.11%
72.00
0.00
—
Financing Cash Flow
214.87
+286.36%
55.62
-44.95%
101.03
+77.92%
56.78
Cash Flow From Continuing Financing Activities
214.87
+286.36%
55.62
-44.95%
101.03
+77.92%
56.78
Net Common Stock Issuance
210.12
0.00
—
—
Proceeds From Stock Option Exercised
4.76
+4563.73%
0.10
+251.72%
0.03
-92.54%
0.39
Net Other Financing Charges
—
-4.15
—
—
Changes In Cash
1.14
-70.41%
3.87
+448.60%
-1.11
+73.56%
-4.20
Beginning Cash Position
30.53
+14.50%
26.67
-3.99%
27.77
-13.12%
31.97
End Cash Position
31.68
+3.75%
30.53
+14.50%
26.67
-3.99%
27.77
Free Cash Flow
-56.22
-8.81%
-51.67
-57.30%
-32.85
+46.13%
-60.98
Amortization Of Securities
—
-2.90
-288.89%
-0.75
0.00
Common Stock Issuance
210.12
0.00
—
—
Issuance Of Capital Stock
210.12
+252.19%
59.66
-40.93%
101.00
+79.10%
56.39
Net Preferred Stock Issuance
0.00
-100.00%
59.66
-40.93%
101.00
+79.10%
56.39
Preferred Stock Issuance
0.00
-100.00%
59.66
-40.93%
101.00
+79.10%
56.39
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category